BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

850 related articles for article (PubMed ID: 22323599)

  • 1. Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27).
    McCabe MT; Graves AP; Ganji G; Diaz E; Halsey WS; Jiang Y; Smitheman KN; Ott HM; Pappalardi MB; Allen KE; Chen SB; Della Pietra A; Dul E; Hughes AM; Gilbert SA; Thrall SH; Tummino PJ; Kruger RG; Brandt M; Schwartz B; Creasy CL
    Proc Natl Acad Sci U S A; 2012 Feb; 109(8):2989-94. PubMed ID: 22323599
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A687V EZH2 is a driver of histone H3 lysine 27 (H3K27) hypertrimethylation.
    Ott HM; Graves AP; Pappalardi MB; Huddleston M; Halsey WS; Hughes AM; Groy A; Dul E; Jiang Y; Bai Y; Annan R; Verma SK; Knight SD; Kruger RG; Dhanak D; Schwartz B; Tummino PJ; Creasy CL; McCabe MT
    Mol Cancer Ther; 2014 Dec; 13(12):3062-73. PubMed ID: 25253781
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation.
    Yap DB; Chu J; Berg T; Schapira M; Cheng SW; Moradian A; Morin RD; Mungall AJ; Meissner B; Boyle M; Marquez VE; Marra MA; Gascoyne RD; Humphries RK; Arrowsmith CH; Morin GB; Aparicio SA
    Blood; 2011 Feb; 117(8):2451-9. PubMed ID: 21190999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas.
    Sneeringer CJ; Scott MP; Kuntz KW; Knutson SK; Pollock RM; Richon VM; Copeland RA
    Proc Natl Acad Sci U S A; 2010 Dec; 107(49):20980-5. PubMed ID: 21078963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations.
    McCabe MT; Ott HM; Ganji G; Korenchuk S; Thompson C; Van Aller GS; Liu Y; Graves AP; Della Pietra A; Diaz E; LaFrance LV; Mellinger M; Duquenne C; Tian X; Kruger RG; McHugh CF; Brandt M; Miller WH; Dhanak D; Verma SK; Tummino PJ; Creasy CL
    Nature; 2012 Dec; 492(7427):108-12. PubMed ID: 23051747
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Y641C mutation of EZH2 alters substrate specificity for histone H3 lysine 27 methylation states.
    Wigle TJ; Knutson SK; Jin L; Kuntz KW; Pollock RM; Richon VM; Copeland RA; Scott MP
    FEBS Lett; 2011 Oct; 585(19):3011-4. PubMed ID: 21856302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EZH2 W113C is a gain-of-function mutation in B-cell lymphoma enabling both PRC2 methyltransferase activation and tazemetostat resistance.
    Chu L; Tan D; Zhu M; Qu Y; Ma X; Song BL; Qi W
    J Biol Chem; 2023 Apr; 299(4):103073. PubMed ID: 36858198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells.
    Fiskus W; Pranpat M; Balasis M; Herger B; Rao R; Chinnaiyan A; Atadja P; Bhalla K
    Mol Cancer Ther; 2006 Dec; 5(12):3096-104. PubMed ID: 17172412
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective inhibition of EZH2 by ZLD10A blocks H3K27 methylation and kills mutant lymphoma cells proliferation.
    Song X; Zhang L; Gao T; Ye T; Zhu Y; Lei Q; Feng Q; He B; Deng H; Yu L
    Biomed Pharmacother; 2016 Jul; 81():288-294. PubMed ID: 27261606
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A687V EZH2 is a gain-of-function mutation found in lymphoma patients.
    Majer CR; Jin L; Scott MP; Knutson SK; Kuntz KW; Keilhack H; Smith JJ; Moyer MP; Richon VM; Copeland RA; Wigle TJ
    FEBS Lett; 2012 Sep; 586(19):3448-51. PubMed ID: 22850114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EZH1 mediates methylation on histone H3 lysine 27 and complements EZH2 in maintaining stem cell identity and executing pluripotency.
    Shen X; Liu Y; Hsu YJ; Fujiwara Y; Kim J; Mao X; Yuan GC; Orkin SH
    Mol Cell; 2008 Nov; 32(4):491-502. PubMed ID: 19026780
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Substrate preferences of the EZH2 histone methyltransferase complex.
    Martin C; Cao R; Zhang Y
    J Biol Chem; 2006 Mar; 281(13):8365-70. PubMed ID: 16431907
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A mutation in the E(Z) methyltransferase that increases trimethylation of histone H3 lysine 27 and causes inappropriate silencing of active Polycomb target genes.
    Stepanik VA; Harte PJ
    Dev Biol; 2012 Apr; 364(2):249-58. PubMed ID: 22182520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deregulation of H3K27 methylation in cancer.
    Martinez-Garcia E; Licht JD
    Nat Genet; 2010 Feb; 42(2):100-1. PubMed ID: 20104248
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oncogenic Y641 mutations in EZH2 prevent Jak2/β-TrCP-mediated degradation.
    Sahasrabuddhe AA; Chen X; Chung F; Velusamy T; Lim MS; Elenitoba-Johnson KS
    Oncogene; 2015 Jan; 34(4):445-54. PubMed ID: 24469040
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin.
    Morin RD; Johnson NA; Severson TM; Mungall AJ; An J; Goya R; Paul JE; Boyle M; Woolcock BW; Kuchenbauer F; Yap D; Humphries RK; Griffith OL; Shah S; Zhu H; Kimbara M; Shashkin P; Charlot JF; Tcherpakov M; Corbett R; Tam A; Varhol R; Smailus D; Moksa M; Zhao Y; Delaney A; Qian H; Birol I; Schein J; Moore R; Holt R; Horsman DE; Connors JM; Jones S; Aparicio S; Hirst M; Gascoyne RD; Marra MA
    Nat Genet; 2010 Feb; 42(2):181-5. PubMed ID: 20081860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunohistochemical and genomic profiles of diffuse large B-cell lymphomas: implications for targeted EZH2 inhibitor therapy?
    Dubois S; Mareschal S; Picquenot JM; Viailly PJ; Bohers E; Cornic M; Bertrand P; Veresezan EL; Ruminy P; Maingonnat C; Marchand V; Lanic H; Penther D; Bastard C; Tilly H; Jardin F
    Oncotarget; 2015 Jun; 6(18):16712-24. PubMed ID: 25762637
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Down-regulation of the histone methyltransferase EZH2 contributes to the epigenetic programming of decidualizing human endometrial stromal cells.
    Grimaldi G; Christian M; Steel JH; Henriet P; Poutanen M; Brosens JJ
    Mol Endocrinol; 2011 Nov; 25(11):1892-903. PubMed ID: 21903722
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CDK1-dependent phosphorylation of EZH2 suppresses methylation of H3K27 and promotes osteogenic differentiation of human mesenchymal stem cells.
    Wei Y; Chen YH; Li LY; Lang J; Yeh SP; Shi B; Yang CC; Yang JY; Lin CY; Lai CC; Hung MC
    Nat Cell Biol; 2011 Jan; 13(1):87-94. PubMed ID: 21131960
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of hPHF1 in H3K27 methylation and Hox gene silencing.
    Cao R; Wang H; He J; Erdjument-Bromage H; Tempst P; Zhang Y
    Mol Cell Biol; 2008 Mar; 28(5):1862-72. PubMed ID: 18086877
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 43.